Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - imunološke za suidae - svinja (za tov) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Europska Unija - hrvatski - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - cjepiva - active immunisation against h5 subtype of influenza a virus.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ceva santé animale - inaktiviran coxiella burnetii cjepivo, soj nine mile - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - rekombinantni verotoxin 2e e. coli - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium, immunologicals for suidae - svinje - aktivna imunizacija praščića od 2 dana starosti kako bi se spriječila smrtnost i smanjili klinički znakovi bolesti edema (uzrokovanog verotoksinom 2e koji proizvodi e. coli) i smanjiti gubitak dnevne debljanja tijekom završnog razdoblja u lice infekcija s verotoksinom 2e proizvodnjom e. coli do klanja od 164 dana starosti.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - e. coli adhesin f4 (f4ab, f4ac, f4ad), e. coli adhesin f5, e. coli adhesin f6, e. coli adhesin f41 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - sows; sows (nullipar) - smanjenje neonatalne enterotoksikoze prasadi uzrokovano e. coli, koji eksprimiraju adhezinje f4ab, f4ac, f4ad, f5, f6 i f41 tijekom prvih dana života.

Europska Unija - hrvatski - EMA (European Medicines Agency)

intervet international b.v. - svinjski circovirus tip 2 orf2 podjedinica antigena - immunologicals for suidae, inactivated viral vaccines - svinje - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.

Europska Unija - hrvatski - EMA (European Medicines Agency)

intervet international b.v. - svinjske цирковирус tipa 2 (pcv2) podjedinica antigen orf2, микоплазмы hyopneumoniae soja j инактивированная - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinja (za tov) - za aktivne imunizacije svinja za smanjenje виремии, virusne opterećenje u pluća i лимфоидных tkivima, izlučivanje virusa uzrokovana svinjske цирковирус tipa 2 (pcv2) infekcije i težini lezije pluća uzrokovane mycoplasma hyopneumoniae infekcije. kako bi se smanjio gubitak dnevne debljanja tijekom razdoblja završetka u lice infekcija s mycoplasma hyopneumoniae i / ili pcv2 (kao što je vidljivo u terenskim studijama).

Europska Unija - hrvatski - EMA (European Medicines Agency)

zoetis belgium sa - cjepivo svinjske цирковирус (inaktivirano, rekombinantni) - immunologicals for suidae, inactivated viral vaccines - svinja (za tov) - za aktivne imunizacije svinja s 3 tjedna starosti protiv svinjske цирковирус tipa 2 (pcv2) za smanjenje količine virusa u krvi i лимфоидных tkiva i fekalne prolijevanja, uzrokovane infekcijom s ЦВС2.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - svinje - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Europska Unija - hrvatski - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - svinje - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.